Evidence of Benefit with Molecular Profiling

[Fictional]

This from another one of those free CME sites that cater to doctors. It is from CCO's review of the AACR Meeting-

The key points are that profiling identified a target in 98% patients (often those that otherwise would not have been suspected; some tumor shrinkage in 47% - mostly stability, but 10% with partial or complete responses.

"In the 66 patients treated according to molecular profiling results, 27% (95% CI: 17% to 38%) had a progression-free survival ratio ≥ 1.3 (P = .007, 1-sided sample). The null hypothesis was that ≤ 15% of patients would have a progression-free survival ratio ≥ 1.3; these results reject the null hypothesis and lend support to the molecular profiling approach. The investigators were encouraged to see that the median overall survival for patients with a progression-free survival ratio ≥ 1.3 was significantly longer than that for the overall cohort (9.7 vs 5.0 months, respectively; P = .026). Molecular profiling identified a target in 98% of patients. The targets were often surprising and not those that normally would have been suspected, such as 1 patient who was successfully treated with diethylstibestrol for metastatic breast cancer. The overall response rate in the cohort was 10% (2% with a complete response, 8% with a partial response), and 21% of individuals were progression free at 4 months. Some tumor shrinkage was seen at some point during therapy in 47% of patients. Interestingly, for all 18 patients who had a progression-free survival ratio ≥ 1.3, the treatment that would have been selected by the treating physician did not match the therapies identified by molecular profiling."